Dengue Fever Vaccines
Name
|
Marketing Authorisation Holder
|
Kind of Vaccine
|
License Number
|
License Date
|
Further Information
|
Qdenga
|
Tetravalenter Dengue-Impfstoff (lebend, attenuiert)
Verwendung ab einem Lebensalter von 4 Jahren / Use from 4 years of age onwards
|
Takeda GmbH
|
Mono |
EU/1/22/1699 |
05.12.2022 |
EPAR: Qdenga
|
Dengvaxia
|
Tetravalenter Dengue-Impfstoff (lebend, attenuiert)
Für Menschen zwischen 9 und 45 Jahren bestimmt, die in der Vergangenheit bereits mit dem Dengue-Virus infiziert waren und in Endemiegebieten leben
|
Sanofi Pasteur, F-69007 Lyon
|
Mono |
EU/1/18/1338 |
12.12.2018 |
EPAR
|
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 519 in BAnz AT 26.07.2024 B6.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.